Kymera Therapeutics announced a significant licensing deal with Gilead Sciences to develop oral molecular glue degraders targeting proteins implicated in breast cancer. This partnership could yield up to $85 million upfront for Kymera. Simultaneously, Kymera’s collaboration with Sanofi experiences a strategic shift; Sanofi is advancing a different protein degrader candidate, KT-485, for autoimmune diseases into clinical trials, retreating from a previous program. These developments reaffirm Kymera's position in targeted protein degradation, attracting major pharma interest. Leerink Partners views the Gilead collaboration as validation of Kymera’s therapeutic approach amid competitive interest in CDK2 as a cancer target.